Methods of treating hematologic cancers

Abstract

The present application relates to treatment of hematologic cancers, which treatments can include, e.g., administration of a purine nucleoside phosphorylase (PNP) inhibitor, an alkylating agent and/or an anti-CD20 agent, and related compositions and kits.

What is claimed is: 
     
         1 . A method of treating a hematologic cancer in a subject comprising the steps of:
 a. administering to the subject an effective amount of a purine nucleoside phosphorylase (PNP) inhibitor; and   b. administering to the subject an effective amount of an alkylating agent or an anti-CD20 agent.   
     
     
         2 . A method of treating a hematologic cancer in a subject comprising the steps of:
 a. administering to the subject an effective amount Forodesine; and   b. administering to the subject an effective amount of Rituximab.   
     
     
         3 . The method of  claim 2  further comprising administering to the subject an effective amount of an alkylating agent. 
     
     
         4 . The method of  claim 3 , wherein the alkylating agent is selected from a mustard derivative, a nitrosourea derivative, a platinum compound, and an imidazole carboxamide compound. 
     
     
         5 . The method of  claim 3 , wherein the alkylating agent is a mustard derivative. 
     
     
         6 . The method of  claim 3 , wherein the alkylating agent is Bendamustine. 
     
     
         7 . The method of  claim 2 , wherein Forodesine and Rituximab are administered concurrently. 
     
     
         8 . The method of  claim 2 , wherein Forodesine and Rituximab are administered sequentially. 
     
     
         9 . The method of  claim 2 , wherein the Rituximab is administered one or more times prior to administration of Forodesine. 
     
     
         10 . The method of  claim 2 , wherein the hematologic cancer non-Hodgkin's lymphoma. 
     
     
         11 . The method of  claim 2 , wherein the hematologic cancer is chronic lymphocytic leukemia. 
     
     
         12 . The method of  claim 2 , wherein the hematologic cancer is acute lymphoblastic leukemia. 
     
     
         13 . The method of  claim 3 , wherein Forodesine, Rituximab and the alkylating agent are administered concurrently. 
     
     
         14 . The method of  claim 3 , wherein Forodesine, Rituximab and the alkylating agent are administered sequentially. 
     
     
         15 . The method of  claim 14 , wherein Rituximab and the alkylating agent are administered one or more times prior to administration of Forodesine. 
     
     
         16 . The method of  claim 2 , wherein the subject resistant to one or more chemotherapeutic agents. 
     
     
         17 . A pharmaceutical composition comprising Forodesine and Rituximab. 
     
     
         18 . The composition of  claim 17  further comprising an alkylating agent. 
     
     
         19 . The composition of  claim 18  that comprises Forodesine, Bendamustine and Rituximab. 
     
     
         20 . A kit comprising Forodesine and Rituximab. 
     
     
         21 . The kit of  claim 20 , further comprising an alkylating agent. 
     
     
         22 . The kit of  claim 20 , further comprising a delivery system for at least one of Forodesine, Rituximab and the alkylating agent. 
     
     
         23 . The kit of  claim 20 , further comprising instructions for treating a subject. 
     
     
         24 . The kit of  claim 21  that comprises Forodesine, Rituximab and Bendamustine.